The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.